Drugs / glasmacinal
glasmacinal
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 missed | ||||||
| Phase 1 | NCT06677918 | Feb → Aug 2025 | — | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT06118684 | Oct 2023 → Jan 2024 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05516316 | Oct 2022 → Jun 2023 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | Missed primary |
| Phase 1 | NCT04819854 | Apr 2021 → Mar 2022 | adult acute lymphoblastic leukemia | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05572333 | Nov 2022 → Nov 2023 | chronic obstructive pulmonary disease | EpiEndo Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-10-05 | EpiEndo Pharmaceuticals | Results ERJ Open Research publication shows glasmacinal enhances antiviral responses in airway cells from asthma patients epiendo.com ↗
The article shows that glasmacinal enhances the antiviral response while reducing viral load in rhinovirus-infected bronchial epithelial cells obtained from asthma patients with moderate disease. |
| 2026-03-24 | EpiEndo Pharmaceuticals | Results New publication shows glasmacinal reduces eosinophilic airway inflammation in preclinical models epiendo.com ↗
The article shows that glasmacinal reduces eosinophilic inflammation in two established preclinical models of allergic airway disease. |
| 2026-03-18 | EpiEndo Pharmaceuticals | Results British Journal of Clinical Pharmacology article reports two clinical pharmacology trials of glasmacinal (EP395) epiendo.com ↗
Glasmacinal, a macrolide with negligible antimicrobial activity but with anti-inflammatory and immunomodulatory properties, was well tolerated in healthy participants and has limited potential for clinically relevant drug interactions. |
| 2025-12-08 | EpiEndo Pharmaceuticals | Results ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients epiendo.com ↗
Glasmacinal was well-tolerated and reduced neutrophilic inflammation in sputum. |
| 2025-11-17 | EpiEndo Pharmaceuticals | Results Data presentation at British Thoracic Society Winter Meeting epiendo.com ↗
The presentation, ‘EP395, a novel non-antibiotic macrolide, enhances antiviral responses in bronchial epithelial cells from asthma patients’, will highlight preclinical data produced through EpiEndo’s collaboration with Lund University. |
| 2025-06-11 | EpiEndo Pharmaceuticals | Results Clinical and pre-clinical data on the novel Barriolide, EP395 (glasmacinal), published in three articles in Pulmonary Pharmacology and Therapeutics epiendo.com ↗
The article “Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial” reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. |
| 2024-08-15 | EpiEndo Pharmaceuticals | Results EpiEndo to present three posters at ERS Congress 2024 epiendo.com ↗
The first poster details preclinical data, some of which was produced in collaboration with King’s College London, showing that EP395 is effective in the reduction of eosinophilic inflammation. |
| 2024-04-10 | EpiEndo Pharmaceuticals | Results EpiEndo reports Phase 2A results for lead asset, EP395, in COPD epiendo.com ↗ |
| 2023-10-23 | EpiEndo Pharmaceuticals | Results Completion of proof of pharmacology study for lead asset EP395 epiendo.com ↗
Although the primary endpoint (a statistically significant effect on IL-8) was not met, there were positive effects seen on a number of markers of inflammation and epithelial function with EP395 treatment. |
| 2023-08-16 | EpiEndo Pharmaceuticals | Results Poster presentations at ERS Milan 2023 International Congress epiendo.com ↗
The second poster presentation outlines the in vivo inflammation resolving effect of EP395, particularly its role in host-microbe interactions, and its ability to alleviate inflammation and inhibit vascular permeability. |
| 2022-11-14 | EpiEndo Pharmaceuticals | Regulatory Commencement of Ph2a trial for EP395 in COPD patients epiendo.com ↗
EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. |
| 2022-05-18 | EpiEndo Pharmaceuticals | Results Successful completion of Phase I Study for lead asset EP395 epiendo.com ↗
EP395 was well tolerated and with pharmacokinetics consistent with once daily dosing. |
| 2021-01-05 | EpiEndo Pharmaceuticals | Regulatory EpiEndo Receives CTA Approval from UK MHRA for First-in-Man Trials of Lead Compound EP395 epiendo.com ↗
EpiEndo Pharmaceuticals announced today that the Company has received approval of its Clinical Trial Application (CTA) from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to commence phase 1 clinical trials of EP395, the Company's lead compound. |
All press releases naming this drug 20 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glasmacinal | “EP395 (glasmacinal), a novel macrolide, is being developed as a treatment to reduce exacerbations of COPD without inducing antimicrobial resistance.” PMID 42206016 ↗ May 20262“glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.” PMID 41845869 ↗ Mar 2026 “glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.” PMID 41845869 ↗ Mar 2026 |
| Known as | EP395 | “glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions.” PMID 41845869 ↗ Mar 2026 |
| Known as | EP395 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068055 ↗ |
| Modality | Small molecule | “oral anti-inflammatory macrolide” PMID 41845869 ↗ Mar 2026 |
| Route | Oral | “administered by oral capsules” NCT04819854 ↗ |